RECIST — learning from the past to build the future

RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group

(2016) Lawrence H. Schwartz et al.   EUROPEAN JOURNAL OF CANCER

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

(2016) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Pseudoprogression and Immune-Related Response in Solid Tumors

(2015) Victoria L. Chiou et al.   JOURNAL OF CLINICAL ONCOLOGY

Response assessment criteria for brain metastases: proposal from the RANO group

(2015) Nancy U Lin et al.   LANCET ONCOLOGY

Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice

(2014) Andrew G. Robinson et al.   EUROPEAN JOURNAL OF CANCER

The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases

(2014) Gaia Schiavon et al.   EUROPEAN JOURNAL OF CANCER

Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data Warehouse

(2014) Sumithra J. Mandrekar et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors

(2013) R. L. Korn et al.   CLINICAL CANCER RESEARCH

Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials

(2013) C. Ferte et al.   CLINICAL CANCER RESEARCH

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy

(2012) N. Penel et al.   ANNALS OF ONCOLOGY

Progression-Free Survival: Meaningful or Simply Measurable?

(2012) Christopher M. Booth et al.   JOURNAL OF CLINICAL ONCOLOGY

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology

(2012) Beth Sherrill et al.   OncoTargets and Therapy

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Issues in Using Progression-Free Survival When Evaluating Oncology Products

(2009) Thomas R. Fleming et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer clinical trial outcomes: Any progress in tumour-size assessment?

(2008) Jaap Verweij et al.   EUROPEAN JOURNAL OF CANCER

Individual patient data analysis to assess modifications to the RECIST criteria

(2008) Jan Bogaerts et al.   EUROPEAN JOURNAL OF CANCER

Validation of novel imaging methodologies for use as cancer clinical trial end-points

(2008) D.J. Sargent et al.   EUROPEAN JOURNAL OF CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER